For every 10 cancer patients treated, an average of only half will benefit. For some, the treatment won't have any effect; others may suffer from serious side effects.1 Ventana Medical Systems, Inc. (Ventana) is working at our industry's forefront to change this dynamic by customizing therapy to individual patients, helping you to improve diagnostic accuracy, lab efficiency and patient safety.
In collaboration with leading pharmaceutical companies, we identify and develop innovative companion diagnostics to target those patients who are likely to respond to specific therapies. Because we recognize the tremendous potential for these solutions, we continue to focus on addressing unmet medical needs by developing the cutting-edge tools you need.
You can be confident that VENTANA products, only from Roche, are the right solution to empower you to deliver the highest-quality diagnostic information for patients — today and in the future.
"We see an enormous potential and huge opportunities in PHC. Targeted therapies and diagnostic tests that help to improve medical decision making not only offer clinical benefits for patients but are also attractive through health economic benefits to regulatory authorities and payers."
— Severin Schwan, CEO Roche
1. Source: Roche Personalized Healthcare brochure, 2011